 |
인쇄하기
취소
|
Government to support Chong Kun Dang’s dyslipidemia drug development
Chong Kun Dang Pharmaceutical said last Monday it has signed an agreement with the state-run Korea Drug Development Fund (KDDF).
The company plans to carry out clinical trials for its dyslipidemia drug candidate as part of the KDDF program to cultivate blockbuster drugs, targeting the global market.
Under an agreement, the KDDF will provide subsidies for the company’s clinical trials at ...
The company plans to carry out clinical trials for its dyslipidemia drug candidate as part of the KDDF program to cultivate blockbuster drugs, targeting the global market.
Under an agreement, the KDDF will provide subsidies for the company’s clinical trials at ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.